SRC and neoplasm: SRC inhibitors have long been recognised as potential anti‐invasive/metastatic agents to help improve progression‐free survival and metastasis‐free progression [13, 56, 57, 68], yet most clinical trial studies incorporating SRC inhibitors monitor primary tumour growth or regression as a clinical endpoint.